Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Achilles heel spotted for promising HIV-prevention drug

Bimonthly injections of cabotegravir kept most people free of HIV, but in rare cases the drug hid infections and fuelled resistance, study finds.
  1. Amy Maxmen
    View author publications

    You can also search for this author in PubMed  Google Scholar

An injectable drug that was lauded last year for being able to prevent HIV infection looks less perfect today, in light of a new analysis.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 591, 357-358 (2021)

doi: https://doi.org/10.1038/d41586-021-00618-7

Updates & Corrections

  • Correction 09 March 2021: This story was updated to correct Michael Robertson’s location. He works at Merck Research Laboratories in West Point, Pennsylvania, not Boston, Massachusetts.

References

  1. Van Damme, L. et al. N. Engl. J. Med. 367, 411–422 (2012).

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links